Related Experiment Videos
SLP-2 overexpression could serve as a prognostic factor in node positive and HER2 negative breast cancer
Wenfeng Cao1, Bin Zhang, Jin Li
1Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Breast Cancer Research, Tianjin.
Aims:
This study aimed to evaluate the utility as a prognostic factor of SLP-2 on the outcome of breast cancer patients.
Methods:
We performed immunohistochemical analysis to examine the SLP-2 expression in a large panel of invasive breast cancer samples.
Results:
Of the 496 samples, 261 showed overexpression of SLP-2. Importantly, there were significant associations between SLP-2 overexpression and tumour size (p = 0.002), lymph node/distant metastases, clinical stage (p < 0.001), HER2/neu expression (p = 0.003). In addition, there were obvious differences in levels of SLP-2 expression within four molecular subtypes of breast cancer (p = 0.011). High level SLP-2 expression was shown in tumour samples of HER2 and luminal B subtypes, and low level SLP-2 expression was shown in luminal A and triple negative subtypes, suggesting that overexpression of SLP-2 was closely correlated with HER2/neu expression, and that both SLP-2 and HER2/neu can play a role in lymph node/distant metastases of breast cancers. Thus lymph node status, HER2/neu and SLP-2 high-level expression can act as independent prognostic factors.
Conclusions:
There is an obvious link between SLP-2 and HER2/neu expression. Overexpression of SLP-2 is associated with poorer total survival, especially in lymph node positive coupled with HER2/neu negative patients.
